OBIO
Orchestra BioMed Holdings Inc.
NASDAQ: OBIO · HEALTHCARE · BIOTECHNOLOGY
$3.80
-2.56% today
Updated 2026-04-29
Market cap
$239.94M
P/E ratio
—
P/S ratio
7.17x
EPS (TTM)
$-1.11
Dividend yield
—
52W range
$2 – $5
Volume
0.2M
Orchestra BioMed Holdings Inc. (OBIO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.70M | $-782000.00 | $3.53M | $2.76M | $2.64M | $33.48M |
| Revenue growth (YoY) | — | -113.7% | +551.8% | -21.9% | -4.4% | +1169.2% |
| Cost of revenue | $145000.00 | $199000.00 | $322000.00 | $186000.00 | $204000.00 | $190000.00 |
| Gross profit | $5.56M | $-981000.00 | $3.21M | $2.57M | $2.43M | $33.29M |
| Gross margin | 97.5% | 125.4% | 90.9% | 93.3% | 92.3% | 99.4% |
| R&D | $13.48M | $12.89M | $21.95M | $33.82M | $42.80M | $58.19M |
| SG&A | $10.83M | $7.93M | $14.03M | $20.26M | $23.93M | $26.91M |
| Operating income | $-18.75M | $-21.80M | $-32.66M | $-51.51M | $-64.30M | $-51.81M |
| Operating margin | -328.8% | 2787.6% | -924.3% | -1866.2% | -2437.5% | -154.7% |
| EBITDA | $-18.61M | $-21.62M | $-32.44M | $-51.22M | $-63.99M | $-51.48M |
| EBITDA margin | -326.4% | 2764.5% | -918.1% | -1855.8% | -2425.8% | -153.8% |
| EBIT | $-18.75M | $-21.80M | $-32.66M | $-51.51M | $-64.30M | $-51.81M |
| Interest expense | — | $927000.00 | — | — | — | $1.15M |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-21.36M | $-23.01M | $-33.61M | $-49.12M | $-61.02M | $-52.95M |
| Net income growth (YoY) | — | -7.8% | -46.0% | -46.2% | -24.2% | +13.2% |
| Profit margin | -374.5% | 2943.0% | -951.3% | -1779.7% | -2313.3% | -158.2% |